News Release
2020.02.19
Joint Research to Investigate the Efficacy of SB623 in the Treatment of Traumatic Brain Injury at Subacute Phase
News Release
2020.01.24
Joint Research with View to Developing Regenerative Medicine Product for Type 1 Diabetes by Producing Pancreatic Beta Cells Through Direct Reprogramming of Bone Marrow-Derived Mesenchymal Stem Cells
Info
2019.12.16
Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019
News Release
2019.12.16
Q&A Regarding Announcements on December 13, 2019 Concerning “Consolidated Financial Results for the Nine Months Ended October 31, 2019” and “Decision to Terminate a Joint Development and License Agreement for Regenerative Cell Medicine SB623 for Chronic Stroke in North America,”
News Release
2019.12.13
SanBio and Sumitomo Dainippon Pharma Announce a Termination of a Joint Development and License Agreement for Regenerative Cell Medicine SB623 for Chronic Stroke in North America
News Release
2019.09.20
Agreement on Joint Research into SB623 for Indication of Retinal Disease
News Release
2019.09.19
SanBio Granted Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits Secondary to Traumatic Brain Injury
News Release
2019.09.13
SanBio announced the results of the Phase 2 STEMTRA trial of SB623 as a treatment for chronic motor deficit from traumatic brain injury, at 2019 World Federation of Neurosurgical Societies Special World Congress
News Release
2019.08.30
SanBio announced the results of the Phase 2 STEMTRA trial of SB623 as a treatment for chronic motor deficit from traumatic brain injury was presented at the Military Health System Research Symposium 2019
News Release
2019.05.15
Bijan Nejadnik, M.D., appointed as Chief Medical Officer of SanBio
News Release
2024.03.26
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2024.03.18
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2023.12.14
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2023.08.31
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2023.06.14
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2022.12.21
Establishment of In-House Facility and Acquisition of License for Packaging, Labeling and Storage of Regenerative Medicine Products
News Release
2022.11.29
Joint Research Agreement for SB623 Targeting Alzheimer’s-Type Dementia
News Release
2022.10.20
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2022.08.01
Notice regarding appointment of new corporate officers
News Release
2022.07.22
Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Media
2022.04.08
On April 7, NeurologyLive published an interview with Dr. Peter McAllister regarding the final analysis of the Phase 2 STEMTRA trial.
Media
2018.04.20
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, publishes report in the leading medical journal, Stroke
Info
2022.12.22
Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury
Info
2021.02.22
Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan
Info
2021.01.06
SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Info
2019.12.16
Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019
Info
2018.12.27
【Announcement】SanBio will present at the 37th Annual J.P. Morgan Healthcare Conference
Info
2018.08.28
【Announcement】SanBio will be featured on NHK WORLD – JAPAN “Medical Frontiers – The Brain Can Be Regenerated” on September 4 (Tue) 4 times a day, Japan timeIt is available for watching on the Internet.
Info
2018.01.10
SanBio presented at the 36th Annual J.P. Morgan Healthcare Conference
Info
2017.11.22
Keita Mori, CEO of SanBio will speak at 2017 World Alliance Forum in San Francisco on November30
Info
2017.11.22
SanBio will present at 2nd DIA Cell Therapy Products Symposium in Japan on December 15"Quality of Regenerative Medical Products -What do we need to start a clinical study in Japan? -" Takehiko Kaneko, Medical Director & Head of Clinical Development Japan, SanBio Co., Ltd.
Info
2017.05.10
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio will speak at the 7th Annual Traumatic Brain Injury Conference on May 24&25, 2017, Washington DCDr. Bates will be presenting at the 2017 Conference on the subject of San-Bio’s upcoming STEMTRA trial in TBI. Dr. Bates will also participate in the panel session called Milestones and Existing Challenges in Preclinical and Clinical Development of TBI Therapeutics.